Renal Artery Denervation for Hypertension
Purpose of review
Hypertension (HTN) has a growing impact, already affecting over 1 billion people. An estimated 2–16% of those with HTN have resistant HTN. The sympathetic nervous system (SNS) is a recognized contributor to the pathophysiology of resistant HTN. Current hypertensive pharmacotherapy has not fully targeted the SNS; therefore, the SNS has become a prominent research therapeutic target. This review summarizes the evidence and rationale behind renal denervation (RDN) therapy and the technology available.
Prior to the SYMPLICITY HTN-3 clinical trial, trials found RDN to be an effective procedure to control resistant hypertension. The failure of SYMPLICITY HTN-3 to meet its primary efficacy endpoint sparked further studies to address potential shortcomings. The subsequent SPYRAL program trials demonstrated efficacy of RDN therapy in a controlled manner; however, they were not adequately powered. Ongoing research is examining new, innovative RDN technology as well as defining appropriate patients to target for treatment.
The data currently available for RDN in HTN and other states of SNS activation suffer from potential biases and limitations, highlighting the need for continued exploration. Contemporary studies are more promising and hypothesis-generating. Future trials and continued device innovation will be crucial for understanding the clinical applications of RDN therapy.
KeywordsRenal denervation Resistant hypertension Sympathetic nervous system
Compliance with Ethical Standards
Conflict of Interest
Lauren S. Ranard and Rajesh V. Swaminathan declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–50. https://doi.org/10.1161/circulationaha.115.018912.CrossRefPubMedPubMedCentralGoogle Scholar
- 2.Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension prevalence and control among adults: United States, 2015-2016. NCHS data brief. 2017(289):1–8.Google Scholar
- 5.Arima H, Barzi F, Chalmers J. Mortality patterns in hypertension. J Hypertens. 2011;29(Suppl 1):S3–7. https://doi.org/10.1097/01.hjh.0000410246.59221.b1.CrossRefPubMedGoogle Scholar
- 6.Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2017;71:e13–e115. https://doi.org/10.1161/hyp.0000000000000065.CrossRefPubMedGoogle Scholar
- 11.Lloyd-Jones DM, Evans JC, Larson MG, O’Donnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure—factors associated with lack of blood pressure control in the community. Hypertension. 2000;36(4):594–9. https://doi.org/10.1161/01.Hyp.36.4.594.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Zheng L, Li J, Sun Z, Yu J, Zhang X, Zhang X, et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in rural Community of Liaoning Province, China. J Health Sci. 2007;53(2):209–14. https://doi.org/10.1248/jhs.53.209.CrossRefGoogle Scholar
- 13.Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse north american settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 2002;4(6):393–404. https://doi.org/10.1111/j.1524-6175.2002.02045.x.CrossRefGoogle Scholar
- 18.Sata Y, Head GA, Denton K, May CN, Schlaich MP. Role of the sympathetic nervous system and its modulation in renal hypertension. Frontiers in Medicine. 2018.Google Scholar
- 21.• Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81. https://doi.org/10.1016/s0140-6736(09)60566-3This study was the first proof-of-concept trial to evaluate RDN. The trial demonstrated that catheter-based denervation led to a substantial BP reduction without serious adverse events.CrossRefGoogle Scholar
- 22.Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911–7. https://doi.org/10.1161/hypertensionaha.110.163014 Symplicity HTN-1 Investigators.
- 23.Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622–9. https://doi.org/10.1016/S0140-6736(13)62192-3.CrossRefGoogle Scholar
- 24.•Esler M, Krum H, Sobotka P, Schlaich M, Schmieder R, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9. https://doi.org/10.1016/S0140-6736(10)62039-9A multicentre RCT examining RDN versus control in patients with resistant hypertension. Catheter based RDN was demonstrated to lead to a substantial reduction in BP.CrossRefGoogle Scholar
- 25.Staessen JA, Den Hond E, Celis H, Fagard R, Keary L, Vandenhoven G, et al. Antihypertensive treatment based on blood pressure measurement at home or in the physician's office: a randomized controlled trial. JAMA. 2004;291(8):955–64. https://doi.org/10.1001/jama.291.8.955.CrossRefPubMedGoogle Scholar
- 26.•Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014;64(11):1071–8. https://doi.org/10.1016/j.jacc.2014.05.012SYMPLICITY HTN-3 was a pivotal, prospective, sham-controlled study that did not demonstrate any benefit in the use of RDN for reduction of ambulatory BP compared to sham.CrossRefPubMedGoogle Scholar
- 28.Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D'Agostino R, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. JACC. 2015;65(13):1314–21. https://doi.org/10.1016/j.jacc.2015.01.037.CrossRefPubMedGoogle Scholar
- 29.•Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219–27. https://doi.org/10.1093/eurheartj/ehu441This is a post hoc analyses of the SYMPLICITY HTN-3 investigating possible reasons for its’ disparate results. Possible confounding factors identified included: baseline office BP, aldosterone antagonist use, number of ablations performed and non-use of vasodilators.CrossRefPubMedGoogle Scholar
- 30.Kario K, Bhatt DL, Kandzari DE, Brar S, Flack JM, Gilbert C, et al. Impact of renal denervation on patients with obstructive sleep apnea and resistant hypertension—insights from the SYMPLICITY HTN-3 trial. Circ J. 2016;80(6):1404–12. https://doi.org/10.1253/circj.CJ-16-0035.CrossRefPubMedGoogle Scholar
- 31.Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957–65. https://doi.org/10.1016/S0140-6736(14)61942-5.CrossRefPubMedGoogle Scholar
- 32.•• Azizi M, Pereira H, Hamdidouche I, Gosse P, Monge M, Bobrie G, et al. Adherence to Antihypertensive Treatment and the Blood Pressure Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial. Circulation. 2016;134:847–57. https://doi.org/10.1161/circulationaha.116.022922A contemporary study examining RDN in addition to standardized stepped-care antihypertensive treatment. A greater decrease in BP was seen with RDN plus standardized stepped-care antihypertensive treatment compared to the medication treatment regimen alone.CrossRefPubMedGoogle Scholar
- 33.•• Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. et al., 2017;390(10108):2160–70. https://doi.org/10.1016/s0140-6736(17)32281-xAn international, multicentre, sham-controlled, proof-of-concept trial examining RDN, using the Symplicity Spyral catheter, in the absence of antihypertensive medications. This study provided biological proof of principle for the BP lowering effect of RDN.
- 34.•• Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–55. https://doi.org/10.1016/s0140-6736(18)30951-6 An international, multicentre, sham-controlled, proof-of-concept trial examining RDN, using the Symplicity Spyral catheter, in the presence of antihypertensive medications. This study demonstrated greater reduction in BP at 6 months in the RDN group compared to sham group.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.•• Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Lancet. 2018, 2335;391(10137):–45. https://doi.org/10.1016/s0140-6736(18)31082-1This study examined RDN using an alternative technology, endovascular ultrasound, to radiofrequency-based denervation. In the absence of antihypertensive medications, endovascular ultrasound RDN reduced ambulatory BP at 2 months compared to sham.
- 36.Tellez A, Rousselle S, Palmieri T, Rate WR, Wicks J, Degrange A, et al. Renal artery nerve distribution and density in the porcine model: biologic implications for the development of radiofrequency ablation therapies. Transl Res. 2013;162(6):381–9. https://doi.org/10.1016/j.trsl.2013.07.002.CrossRefPubMedGoogle Scholar
- 39.Ormiston JA, Watson T, van Pelt N, Stewart R, Stewart JT, White JM, et al. Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12-month results from the Renal Hypertension Ablation System (RHAS) Trial. EuroIntervention. 2013;9(1):70–4. https://doi.org/10.4244/eijv9i1a11.CrossRefPubMedGoogle Scholar
- 40.Verheye S, Ormiston J, Bergmann MW, Sievert H, Schwindt A, Werner N, et al. Twelve-month results of the rapid renal sympathetic denervation for resistant hypertension using the OneShotTM ablation system (RAPID) study. EuroIntervention. 2015;10(10):1221–9. https://doi.org/10.4244/eijy14m12_02.CrossRefPubMedGoogle Scholar
- 41.Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34(28):2132–40. https://doi.org/10.1093/eurheartj/eht197.CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Sievert H, Schofer J, Ormiston J, Hoppe UC, Meredith IT, Walters DL, et al. Bipolar radiofrequency renal denervation with the Vessix catheter in patients with resistant hypertension: 2-year results from the REDUCE-HTN Trial. J Hum Hypertens. 2017;31(5):366–8. https://doi.org/10.1038/jhh.2016.82.CrossRefPubMedGoogle Scholar
- 43.Mauri L, Kario K, Basile J, Daemen J, Davies J, Kirtane AJ, et al. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: the RADIANCE-HTN and REQUIRE clinical study designs. Am Heart J. 2018;195:115–29. https://doi.org/10.1016/j.ahj.2017.09.006.CrossRefPubMedGoogle Scholar
- 46.Bhatt N, Long SA, Gardner EA, Tay J, Ladich E, Chamberlain D, et al. Radiosurgical ablation of the renal nerve in a porcine model: a minimally invasive therapeutic approach to treat refractory hypertension. Cureus. 2017;9(2):e1055. https://doi.org/10.7759/cureus.1055.CrossRefPubMedPubMedCentralGoogle Scholar
- 50.•• Fengler K, Rommel K-P, Blazek S, Besler C, Hartung P, von Roeder M, et al. A three-arm randomized trial of Different Renal Denervation Devices and Techniques in Patients with Resistant Hypertension (RADIOSOUND-HTN). Circulation. 2018;0(0). https://doi.org/10.1161/CIRCULATIONAHA.118.037654First trial to compare the effectiveness of three different strategies for RDN: (1) RF ablation of main renal arteries, (2) RF ablation of main renal arteries, side branches and accessories, and (3) endovascular ultrasound-based RDN of main renal artery. The study demonstrated that denervation using the Paradise endovascular ultrasound system had a greater reduction in ambulatory SBP compared to RF ablation of main renal artery alone.
- 52.Shafi T, Chacko M, Berger Z, Wilson LM, Gayleard J, Bass EB et al. AHRQ Technology Assessments. Renal Denervation in the Medicare Population. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016.Google Scholar
- 53.Flack JM, Bhatt DL, Kandzari DE, Brown D, Brar S, Choi JW, et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015;9(10):769–79. https://doi.org/10.1016/j.jash.2015.08.001.CrossRefPubMedGoogle Scholar
- 55.Coppolino G, Pisano A, Rivoli L, Bolignano D. Renal denervation for resistant hypertension. Cochrane Database Syst Rev. 2017;2. https://doi.org/10.1002/14651858.CD011499.pub2.
- 56.Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202(11):1028–34.Google Scholar
- 58.Kasiakogias A, Tsioufis C, Dimitriadis K, Konstantinidis D, Koumelli A, Leontsinis I, et al. Cardiovascular morbidity of severe resistant hypertension among treated uncontrolled hypertensives: a 4-year follow-up study. J Hum Hypertens. 2018;32(7):487–93. https://doi.org/10.1038/s41371-018-0065-y.CrossRefPubMedGoogle Scholar
- 59.Soliman EZ, Ambrosius WT, Cushman WC, Zhang ZM, Bates JT, Neyra JA, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). Circulation. 2017;136(5):440–50. https://doi.org/10.1161/CIRCULATIONAHA.117.028441.CrossRefPubMedPubMedCentralGoogle Scholar
- 61.Khurshid K, Yabes J, Weiss PM, Dharia S, Brown L, Unruh M, et al. Effect of antihypertensive medications on the severity of obstructive sleep apnea: a systematic review and meta-analysis. J Clin Sleep Med. 2016;12(8):1143–51. https://doi.org/10.5664/jcsm.6054.CrossRefPubMedPubMedCentralGoogle Scholar
- 62.Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, DeFerrari G, Eisner G, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005;16(10):3027–37. https://doi.org/10.1681/asn.2004110919.CrossRefPubMedGoogle Scholar
- 63.Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc.CrossRefGoogle Scholar
- 65.Davies JE, Manisty CH, Petraco R, Barron AJ, Unsworth B, Mayet J, et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol. 2013;162(3):189–92. https://doi.org/10.1016/j.ijcard.2012.09.019.CrossRefPubMedGoogle Scholar
- 66.Gao JQ, Yang W, Liu ZJ. Percutaneous renal artery denervation in patients with chronic systolic heart failure: a randomized controlled trial. Cardiol J. 2018. https://doi.org/10.5603/CJ.a2018.0028.
- 67.Chen W, Ling Z, Xu Y, Liu Z, Su L, Du H, et al. Preliminary effects of renal denervation with saline irrigated catheter on cardiac systolic function in patients with heart failure: a prospective, randomized, controlled. Pilot Study Catheter Cardiovasc Interv. 2017;89(4):E153–e61. https://doi.org/10.1002/ccd.26475.CrossRefPubMedGoogle Scholar
- 68.Schirmer SH, Sayed MM, Reil JC, Ukena C, Linz D, Kindermann M, et al. Improvements in left ventricular hypertrophy and diastolic function following renal denervation: effects beyond blood pressure and heart rate reduction. J Am Coll Cardiol. 2014;63(18):1916–23. https://doi.org/10.1016/j.jacc.2013.10.073.CrossRefPubMedGoogle Scholar
- 69.Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60(13):1163–70. https://doi.org/10.1016/j.jacc.2012.05.036.CrossRefPubMedGoogle Scholar
- 71.Warchol-Celinska E, Prejbisz A, Kadziela J, Florczak E, Januszewicz M, Michalowska I, et al. Renal denervation in resistant hypertension and obstructive sleep apnea. Randomized Proof-of-Concept Phase II Trial. Hypertension. 2018;72:381–90. https://doi.org/10.1161/hypertensionaha.118.11180.CrossRefPubMedGoogle Scholar
- 72.Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123(18):1940–6. https://doi.org/10.1161/circulationaha.110.991869.CrossRefPubMedGoogle Scholar